Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Solid Tumors
Filter by Topic
Bladder Cancer
Breast Cancer
Colon Cancer
Colorectal Cancer
Gastric Cancer
Genitourinary Cancers
GI Cancers
Gynecologic Cancer
Head and Neck Cancer
Liver Cancer
Lung Cancer
Melanoma
Ovarian Cancer
Pancreatic Cancer
Prostate Cancer
Thyroid Cancer
For Oncologists, Some Food for Thought in the New Era of Healthcare Reform
By
Audrey Andrews
Breast Cancer
,
Breast Cancer Symposium
,
Solid Tumors
October 2013, Vol 4, No 8
San Francisco, CA—At the 2013 Breast Cancer Symposium, Lawrence N. Shulman, MD, Senior Vice President for Medical Affairs, Dana-Farber Cancer Institute, Boston, told oncologists that in the current era of healthcare reform, they will need to think beyond treatment outcomes, toxicities, and personal preferences.
Read Article
Number of Metabolic Syndrome Risk Factors Influences Risk for Prostate Cancer
By
Rosemary Frei, MSc
Prostate Cancer
,
Solid Tumors
September 2013, Vol 4, No 7
Niagara Falls, Ontario—Previous studies have shown an association between metabolic syndrome and prostate cancer. A study presented at the 2013 Canadian Urological Association annual meeting during a poster presentation investigated the level of prostate cancer risk in relation to the number of risk factors of metabolic syndrome and prostate cancer grade.
Read Article
MR-Guided Laser Ablation of Prostate Cancer Producing Promising Results
By
Rosemary Frei, MSc
Personalized Medicine
,
Prostate Cancer
,
Solid Tumors
September 2013, Vol 4, No 7
Niagara Falls, Ontario—Magnetic resonance (MR) imaging or MR-guided laser focal therapy for ablating low- to intermediate-risk prostate tumors is showing promise in the hands of a Toronto team, despite a relatively high failure rate.
Read Article
New Technologies Bring No Upward Shift in Treatment of Local Prostate Cancer
By
Wayne Kuznar
Personalized Medicine
,
Prostate Cancer
,
Solid Tumors
September 2013, Vol 4, No 7
Chicago, IL—The rate of therapy for localized prostate cancer does not increase in markets with higher penetration of robotic surgical technology and intensity-modulated radiation therapy (IMRT), according to an examination of trends using the Surveillance, Epidemiology and End Results (SEER)-Medicare–linked database, according to a poster presentation at the 2013 American Society of Clinical Oncology meeting by lead investigator Florian Rudolf Schroeck, MD, MS, Clinical Lecturer, Urology, University of Michigan, Ann Arbor.
Read Article
ASCO Adds Aromatase Inhibitor to Breast Cancer Prevention Options in Postmenopausal Women
By
Charles Bankhead
Breast Cancer
,
Personalized Medicine
,
Solid Tumors
September 2013, Vol 4, No 7
An aromatase inhibitor has joined tamoxifen (Nolvadex) and the selective estrogen receptor (ER) modulator raloxifene hydrochloride (Evista) as chemoprevention for women who are at an increased risk for breast cancer, according to the recent update of the American Society of Clinical Oncology (ASCO) practice guideline (Visvanathan K, et al.
J Clin Oncol
. 2013;31:2942-2962)
Read Article
Strongly Suppressing Testosterone during Androgen-Deprivation Therapy Prolongs Survival
Personalized Medicine
,
Prostate Cancer
,
Solid Tumors
June 2013, Vol 4, No 5
A secondary analysis of a large study on intermittent versus continuous androgen-deprivation therapy (ADT) has confirmed the importance of aiming for very low testosterone levels in men after they are diagnosed with prostate cancer, according to new data presented at the 2013 Canadian Urological Association annual meeting.
Read Article
New Guideline Emphasizes Sequenced Therapy for Castration-Resistant Prostate Cancer
Personalized Medicine
,
Prostate Cancer
,
Solid Tumors
June 2013, Vol 4, No 5
Evidence-based drug sequencing should form the basis of treatment for castration-resistant prostate cancer (CRPC), according to a new guideline from the American Urological Association (AUA) released at the 2013 AUA annual meeting.
Read Article
Higher HER2 Expression Leads to Better Outcomes with T-DM1 in Patients with Metastatic Breast Cancer
By
Phoebe Starr
Breast Cancer
,
Personalized Medicine
,
Solid Tumors
May 2013, Vol 4, No 4
Washington, DC—Among women with HER2-positive metastatic breast cancer, patients with the highest expression of HER2 had the best outcomes in treatment with ado-trastuzumab emtansine (T-DM1; Kadcyla), according to a biomarker analysis of the phase 3 EMILIA trial which was presented at the 2013 American Association for Cancer Research annual meeting.
Read Article
Tumor Subtype Fails to Explain Racial Disparity in Breast Cancer Survival
By
Charles Bankhead
Breast Cancer
,
Personalized Medicine
,
Solid Tumors
May 2013, Vol 4, No 4
Read Article
Budget Impact Model: Epigenetic Assay Can Help Avoid Unnecessary Repeated Prostate Biopsies, Reduce Spending
Prostate Cancer
,
Solid Tumors
May 2013, Vol 4, No 4
This is an abbreviated version of the original article that was recently published in American Health & Drug Benefits. 2013;6(1):15-24.
Read Article
Page 13 of 16
7
8
9
10
11
12
13
14
15
16
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma